Table 1.
Clinical trials of CD46-based cancer therapeutics.
| Name | Category | Target | Phase | Clinicaltrials.gov# | Sponsor |
|---|---|---|---|---|---|
| Enadenotucirev 1 | Oncolytic adenovirus | Epithelial tumors; colorectal cancer; bladder cancer |
Phase 1/2 | NCT02028442 | PsiOxus Therapeutics |
| Enadenotucirev | Oncolytic adenovirus + chemotherapy | Platinum-resistant epithelial ovarian cancer | Phase 1 | NCT02028117 | PsiOxus Therapeutics |
| Enadenotucirev | Oncolytic adenovirus + immunotherapy | Metastatic or advanced epithelial tumors | Phase 1 | NCT02636036 | PsiOxus Therapeutics |
| Enadenotucirev | Oncolytic adenovirus + chemoradiotherapy | Advanced rectal cancer | Phase 1 | NCT03916510 | University of Oxford |
| NG-350A 2 | Oncolytic adenovirus | Advanced or metastatic epithelial tumors | Phase 1 | NCT03852511 | PsiOxus Therapeutics |
| NG-641 2 | Oncolytic adenovirus | Advanced or metastatic epithelial tumors | Phase 1 | NCT04053283 | PsiOxus Therapeutics |
| LOAd703 3 | Oncolytic adenovirus + chemotherapy or immunotherapy | Pancreatic cancer | Phase 1/2 | NCT02705196 | Lokon Pharma AB |
| LOAd703 | Oncolytic adenovirus + immunotherapy | Malignant melanoma | Phase 1/2 | NCT04123470 | Lokon Pharma AB |
| LOAd703 | Oncolytic adenovirus + chemotherapy or immune conditioning | Pancreatic adenocarcinoma; ovarian cancer; biliary cancer; colorectal cancer |
Phase 1/2 | NCT03225989 | Lokon Pharma AB |
| MV-NIS 4 | Oncolytic measles virus + chemotherapy | Cancer of ovaries, fallopian tubes or peritoneal cancer | Phase 2 | NCT02364713 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Squamous cell carcinoma neck/head or breast cancer | Phase 1 | NCT01846091 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Ovarian epithelial cancer; peritoneal cancer | Phase 1 | NCT00408590 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Malignant pleural mesothelioma | Phase 1 | NCT01503177 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Recurrent or refractory multiple myeloma | Phase 1/2 | NCT00450814 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Peripheral nerve sheath tumor; neurofibromatosis type 1 | Phase 1 | NCT02700230 | Mayo Clinic |
| MV-NIS | Oncolytic measles virus | Multiple myeloma | Phase 2 | NCT02192775 | University of Arkansas |
| MV-NIS | Oncolytic measlesvirus-infected mesenchymal stem cells | Recurrent ovarian cancer | Phase 1/2 | NCT02068794 | Mayo Clinic |
| MV-CEA 5 | Oncolytic measles virus | Recurrent glioblastoma multiforme | Phase 1 | NCT00390299 | Mayo Clinic |
| MV-CEA | Oncolytic measles virus | Recurrent ovarian epithelial cancer;primary peritoneal cancer | Phase 1 | NCT00408590 | Mayo Clinic |
| TMV-018 6 | Oncolytic measles virus | Gastrointestinal cancer | Phase 1 | NCT04195373 | Themas Bioscience |
| FOR46 7 | Antibody-drug conjugate | Multiple myeloma, relapsed or refractory | Phase 1 | NCT03650491 | Fortis |
| FOR 46 | Antibody-drug conjugate | Metastatic prostate cancer | Phase 1 | NCT03575819 | Fortis |
1 Chimera derived from adenovirus group BAd11p/Ad3. 2 Transgene-modified variant of Enadenotucirev expressing a bi-specific T-cell activator molecule (FAP-TAc) recognizing fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T-cells. Production of FAP-TAc by virus-infected tumor cells should lead to T cell-mediated killing of CAFs and, thus, modification of the tumor microenvironment to drive effective anti-tumor immunity. 3 LOAd, the virus is a hybrid derived from adenovirus serotypes 5 and 35. It expresses immune-activating genes (trimerized membrane-bound isoleucine zipper TMZ-CD40L and 4-1BB ligand) under control of a cytomegalovirus (CMV) promoter. 4 MV-NIS, an oncolytic measles virus (MV) encoding the thyroidal sodium iodide symporter (NIS) that facilitates viral gene expression and offers a tool for radiovirotherapy. 5 MV-CEA, an oncolytic measles virus encoding the carcinoembryonic antigen (CEA). 6 Oncolytic measles virus, TMV-018-101, engineered with cytosine deaminase. 7 A monoclonal antibody to a conformationally-specific epitope of CD46 expressed only on tumor cells that is conjugated to an anti-cancer drug.